Search the Newsreel

Verrica (NASDAQ: VRCA) CEO buys 25,000 shares in August

Verrica Pharmaceuticals Inc. (VRCA) CEO Jayson Rieger purchased 25,000 shares of common stock in August 2026. These open-market transactions included 5,000 shares bought on August 17 at $4.91 per share and 20,000 shares on August 14 at a weighted average price of $5.06. The …

Verrica (NASDAQ: VRCA) interim CFO adds 5,000 shares in open-market buy

Verrica Pharmaceuticals Inc.'s Interim CFO, John J. Kirby, purchased 5,000 shares of common stock in the open market on August 18, 2026. The shares were bought at a weighted average price of $4.93, with individual trades ranging from $4.85 to $4.99 per share. Following …

Cocrystal Pharma (NASDAQ: COCP) names Carol L. Brosgart to its board

Cocrystal Pharma, Inc. (NASDAQ: COCP) has appointed Carol L. Brosgart as a director to its Board, effective August 12, 2026. The company stated that there are no arrangements or understandings related to her selection, no family relationships with current directors or officers, and no …

Royalty Pharma (NASDAQ: RPRX) holder plans multi-million share sale

SCH Investment Partners LLC intends to sell 100,000 Class A Ordinary Shares of Royalty Pharma (NASDAQ: RPRX) with an aggregate market value of $6,012,000. These shares were acquired in private transactions in 2024 and 2025 and represent a small fraction of Royalty Pharma's 445,277,344 …

LUCIDITY Shows Clear Phase III Win For Amylyx’s Avexitide

Amylyx's Avexitide achieved a clear Phase III win in the LUCIDITY trial for patients with post-bariatric hypoglycemia (PBH). The company plans to submit the drug to the US FDA by the end of 2026. This positive outcome follows a previous late-stage drug failure for …

Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses

Lantern (LTRN) Reported Results Review: EPS Clears the Reported Estimate for the Current Session; Shares Move 3.08% Lower in the Latest Session - Non-GAAP Earnings

These 2 Stocks Are Setting Off Technical Alarm Bells with $1,000+ Price Tags. Here’s the Company I’d Bet on for the Long Term.

Buy Sell cards by Kelly Sikkema via Unsplash Virginia-based conglomerate Graham Holdings (GHC)was one of Barchart's 200 bearish price surprises in Monday trading. It was down 2.2% on the day to $1,165.29; its standard deviation was -1.67, far from the highest, Eyepoint (EYPT), at …

Liminatus Pharma Announced Transfer or Voluntary Withdrawal of Listing

Liminatus Pharma (LIMN) received approval from Nasdaq's Hearings Panel on July 31, 2026, to transfer to The Nasdaq Capital Market, effective August 4, 2026. This approval is contingent upon the company filing a transfer application by August 7 and maintaining a $1.00 closing bid …

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma announced inducement grants totaling 11,000 restricted stock units (RSUs) to newly hired employees. These grants, made on August 17, 2026, are a material inducement for employment, aligning with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal installments over a …

New Zenas BioPharma hires receive stock awards vesting through 2030

Zenas BioPharma announced on August 18, 2026, that its Board Compensation Committee granted 11,000 restricted stock units (RSUs) to newly hired employees as inducement awards. These RSUs, issued under Nasdaq Listing Rule 5635(c)(4) and the company’s 2026 Inducement Plan, will vest in four equal …

Rocket Pharma (NASDAQ: RCKT) sale tied to 2026 vesting, tax bill

Gaurav Shah, associated with Rocket Pharmaceuticals (RCKT), has filed a Rule 144 notice to sell 2,293 shares of restricted common stock. This proposed sale is linked to restricted stock vesting on August 14, 2026, and partially aims to cover a tax obligation from a …

Rocket Pharma (NASDAQ: RCKT) ex-officer to unload equity-award shares

A former officer of Rocket Pharmaceuticals (NASDAQ: RCKT), John Militello, has filed a Form 144 notice to sell 1,252 shares of common stock. The filing, dated August 18, 2026, details two recent restricted stock vesting events in August 2026 and a sale of 384 …

A PTSD treatment designed to build stress resilience gets Canadian patent allowance

Silo Pharma (Nasdaq: SILO) announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for its patent application covering SPC-15, an intranasal 5-HT4 receptor agonist for PTSD and stress-induced psychiatric disorders. This patent, licensed from Columbia University, covers methods to prevent …

Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock

Liminatus Pharma, Inc. announced a 1-for-50 reverse stock split of its common stock, effective at the close of trading on August 20, 2026. This action was approved by stockholders at the 2026 Annual Meeting and aims to adjust the number of outstanding shares without …

Basilea Pharmaceutica AG erhöht Gewinnprognose für das Gesamtjahr 2026

Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $30

Stifel has reiterated its Buy rating on Crescent Biopharma (CBIO.US) and maintained its target price at $30. This suggests a continued positive outlook from the firm regarding the company's stock performance.

Amylyx Pharmaceuticals Inc. (AMLX) Stock Price | Live Quotes & Charts | NASDAQ

Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts (AMLX)

Amylyx Pharmaceuticals (AMLX) has been upgraded to "Strong Buy" following positive Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia (PBH), which met its primary endpoint with a 55% reduction in severe hypoglycemic events and a favorable safety profile. Key upcoming catalysts include …

Xeris Biopharma Holdings (XERS) Could Be 23% Undervalued As Guidance Tightens And Pipeline Progress Continues

Xeris Biopharma Holdings (XERS) is gaining attention after tighter full-year revenue guidance and second-quarter results were released on August 6, 2026. The stock is considered 22.8% undervalued with a fair value of $11.14 per share, compared to its current price of $8.60. This valuation …

Silo (SILO) Technical Check: Adds 1.95% to Close at $3.13; Range and Risk: the $2.97 to $3.29 Range Remains in Focus in the Current Update - Earnings Miss Risk

Takeda Pharmaceutical (TSE:4502) Wins FDA Approval For ORZEYFUL, Is The Stock Still Cheap?

Takeda Pharmaceutical's stock is in focus after its ORZEYFUL drug received FDA approval for narcolepsy type 1, leading to positive share price returns. The company is considered 9% undervalued with a fair value of ¥6,262.69, driven by anticipated earnings recovery post-VYVANSE generic erosion and …

ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year High - Here's What Happened

ACADIA Pharmaceuticals (NASDAQ:ACAD) recently hit a new 52-week high of $29.87, closing near $29.62, driven by positive analyst sentiment and strong financial results. The company's recent earnings exceeded expectations, reporting $0.18 EPS against an anticipated $0.07, and revenue grew 16.4% year-over-year to $308 million. …

Ligand (LGND) Latest Results Brief: EPS Exceeds Its Estimate on the Day; Price Action: The Stock Ends Down 1.27% in Latest Trading - Earnings Call Highlights

Basilea Pharmaceutica Aktie (BSLN) | Aktienkurs » CH0011432447

Why Helix BioPharma Corp. stock is gaining today

Eloxx Pharmaceuticals, Inc. Statistics – FWB:J36

This page provides an overview of financial statistics for Eloxx Pharmaceuticals, Inc. (J36 on the Frankfurt Stock Exchange). It outlines various key financial metrics, valuation ratios, profitability ratios, liquidity ratios, solvency ratios, and per-share metrics. However, all listed data fields for annual and quarterly …

Pablo Legorreta's 101.8M-share Royalty Pharma (NASDAQ: RPRX) stake updated

Pablo Legorreta has updated his beneficial ownership in Royalty Pharma (NASDAQ: RPRX) through an amended SEC filing, reporting a stake of 101.8 million Class A shares, representing 18.73% of the class. This includes shares issuable under an A&R Exchange Agreement, and the recalculation follows …

Ionis (IONS) Financial Update: The Bottom-Line Figure Beats Its Comparison; Closing Response: Shares Finish 1.71% Up - Energy Earnings Report

Traders Buy Large Volume of Call Options on Eyepoint Pharmaceuticals (NASDAQ:EYPT)

EYPT Stock Crashes On Duravyu Data But Catalysts Loom

EyePoint Pharmaceuticals (EYPT) stock initially crashed by 69% after its Phase 3 LUGANO trial for DURAVYU in wet AMD missed its primary vision endpoint on the full dataset. However, an ad hoc analysis, excluding an asymmetric cohort, showed non-inferiority against aflibercept and other strong …

Nuvectis Pharma (NASDAQ:NVCT) Trading 6.2% Higher - What's Next?

Nuvectis Pharma (NASDAQ:NVCT) shares rose 6.2% to $20.265, though trading volume was significantly below average. The company faces mixed analyst ratings, with a consensus "Hold" and a $35 price target, despite missing recent earnings expectations. Insider buying and high institutional ownership (96.77%) characterize the …

Citigroup Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price

Citigroup has significantly cut its price target for Eyepoint Pharmaceuticals (NASDAQ:EYPT) from $35.00 to $17.00, while still maintaining a "buy" rating, indicating a potential upside of 216.10% from its current price of $5.38. This downgrade follows the failure of the company's LUGANO trial for …

ETFs Investing in Eloxx Pharmaceuticals, Inc. Stocks

This article lists ETFs that invest in Eloxx Pharmaceuticals, Inc. stocks, providing details such as market value, weight, issuer, and management style for each fund. It aims to help investors find opportunities with lower risk by investing in these ETFs. The primary ETF mentioned …

BioMarin Pharmaceutical's Alesta Deal Strengthens Long-Term Growth Outlook, Wedbush Says

BioMarin Pharmaceutical's (BMRN) Alesta acquisition adds a new pipeline opportunity and supports long-term growth, Wedbush Securities said in a note Tuesday. The company said earlier Tuesday that it is acquiring Alesta Therapeutics for as much as $490 million with the goal of Silver Upgrade …

China NT Pharma Faces RMB92 Million Arbitration Award Over 2020 Asset Deal